Aurobindo receives FDA approval for colchicine capsules
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application colchicine capsules, 0.6mg.
Pharmacy
NACDS elects 2024-2025 officers, welcomes new members to board and executive committee
PALM BEACH, Fla. – During the 2024 National Association of Chain Drug Stores (NACDS) Annual Meeting, NACDS elected new officers and five newly elected Board of Directors members for the coming year. Additionally, NACDS re-elected two Board of Directors members whose terms were set to expire.
NACDS Foundation welcomes three new members to board
PALM BEACH, Fla. – At the 2024 National Association of Chain Drug Stores (NACDS) Annual Meeting, the NACDS Foundation announced the addition of three new members to the NACDS Foundation Board of Directors. Each Director will serve a one-year term.
CVS buys Medicare Advantage brokerage
According to a report in Modern Healthcare, CVS Health has acquired Medicare Advantage broker platform Hella Health. The online platform offers plans from Aetna, Cigna, Humana, UnitedHealthcare and other major insurers.
NACDS gears up for dramatic change for pharmacy
The National Association of Chain Drug Stores will move from strength to strength when Kevin Host succeeds Mike Wysong as the organization’s chairman during the NACDS Annual Meeting here this week.
Anderson optimistic despite lack of congressional action
The pharmacy industry and National Association of Chain Drug Stores are at an inflection point, says NACDS president and chief executive officer Steve Anderson.
Soleo Health unveils pharmacy in Jackson, Miss.
FRISCO, Texas –Soleo Health, a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi.
Momentum for PBM reform surges
While the National Association of Chain Drug Stores has a full plate of issues to deal with, without question the most pressing is PBM reform.
Camber adds aripiprazole OS to complete product family
PISCATAWAY, N.J. – Camber Pharmaceuticals is thrilled to announce the addition of aripiprazole oral solution to its product line, complementing the existing product family that included aripiprazole tablets.
Walgreens launches gene and cell services, expands specialty Rx arm
Walgreens is expanding its specialty pharmacy services and investing in its capabilities as the company further grows its core pharmacy business to improve patient outcomes and provide greater value to payers and partners.
Deloitte releases 14th Annual Pharmaceutical Innovation Report
Deloitte in a series of annual reports on “Measuring the return from pharmaceutical innovation,” in collaboration with other member firms, has provided insights into the state of biopharma R&D since 2010.
Albertsons enters partnership with NationsBenefits
PLANTATION, Fla. – NationsBenefits, the market leader for supplemental benefits and healthcare fintech solutions serving the healthcare managed care market, has announced that Albertsons Cos. has joined NationsBenefits’ network of grocery and over-the-counter (OTC) retailers.
SnapSlide introduces revolutionary child-resistant cap
SCRANTON, Pa. – SnapSlide, a packaging innovations company dedicated to making it easier for consumers to access, use, and store pharmaceutical products, has introduced a line of no-torque, child-resistant caps that is the market’s first adaptive packaging solution.
Community pharmacists press for PBM reform during packed fly-in
ALEXANDRIA, Va. – On April 17 and 18, hundreds of independent community pharmacists came to Capitol Hill in Washington, D.C., to participate in the National Community Pharmacists Association’s Congressional Pharmacy Fly-In.
Cardinal reaffirms fiscal guidance and long-term targets amidst nonrenewal of OptumRx customer contracts
Cardinal Health announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35.